Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

BACKGROUND: Breakpoint cluster region-Abelson gene (BCR-ABL) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, concern has arisen about the cardiac safety profile of these drugs. OBJECTIVES: This study aims to compare long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nunes, Rafael Amorim Belo, Neves, Precil Diego Miranda de Menezes, da Costa, Leandro Menezes Alves, Bachour, Philip, Cantarelli, Marcelo José de Carvalho, Oliveira, Gustavo Bernardes de Figueiredo, Avezum Jr., Álvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941183/
https://www.ncbi.nlm.nih.gov/pubmed/36824461
http://dx.doi.org/10.3389/fcvm.2023.888366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941183/
https://www.ncbi.nlm.nih.gov/pubmed/36824461
http://dx.doi.org/10.3389/fcvm.2023.888366

Ejemplares similares